Chair and Professor, Medicine (primary) Professor, Clinical Epidemiology and Biostatistics (Associate) Leo Pharma Chair in Thromboembolism Research
Biography
Dr Crowther's research interests include improving the way we use current anticoagulant drugs. These include exploring established and novel interventions to mitigate bleeding, and studies of currently available anticoagulant drugs in high-risk patient populations. Dr Crowther's work also focusses on developing systematic reviews of key questions in Hematology and Thrombosis, and basing Guidelines on those reviews.
Dr Crowther has more than 400 peer reviewed publications, was inducted into the Royal Society of Canada in 2017, and received the 2017 International Society of Thrombosis and Haemostasis BACH Investigator Recognition Award. He was one of 14 scientists from the Michael G. DeGroote School of Medicine at McMaster University cited by Clarivate Analytics on its Highly Cited Researchers list (formerly known as Thomson Reuter's annual publication of The World's Most Influential Scientific Minds).
Dr Crowther is currently the Chair, Department of Medicine at McMaster University and holds the Leo Pharma Chair in Thromboembolism Research at McMaster University.
Dr Crowther has more than 400 peer reviewed publications, was inducted into the Royal Society of Canada in 2017, and received the 2017 International Society of Thrombosis and Haemostasis BACH Investigator Recognition Award. He was one of 14 scientists from the Michael G. DeGroote School of Medicine at McMaster University cited by Clarivate Analytics on its Highly Cited Researchers list (formerly known as Thomson Reuter's annual publication of The World's Most Influential Scientific Minds).
Dr Crowther is currently the Chair, Department of Medicine at McMaster University and holds the Leo Pharma Chair in Thromboembolism Research at McMaster University.
Have you ever wondered about the impact of direct oral anticoagulants (DOACs) on routine coagulation assays and how patients on DOACs can be managed by the clinical laboratory? DOACs have been available for several years to treat atrial fibrillation patients at risk of stroke, as well as patients with venous thromboembolism (VTE). Though routine monitoring is not required for patients taking DOACs, screening or measurement assays could help in some emergency patient management situations. Dr Crowther’s webinar will cover this hot topic, which regularly impacts patients in critical care settings.
